CCCC

2.30

6.48% 0.14

Handel nachbörslich: 2.29 -0.010 -0.43%

C 4 Therapeutics Inc (CCCC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.16

Offen:

$2.15

24-Stunden-Volumen:

1.61M

Relative Volume:

1.09

Marktkapitalisierung:

$222.90M

Einnahmen:

$20.76M

Nettoeinkommen (Verlust:

$-132.49M

KGV:

-0.8614

EPS:

-2.67

Netto-Cashflow:

$-108.55M

1W Leistung:

+21.69%

1M Leistung:

+6.98%

6M Leistung:

-11.88%

1J Leistung:

-23.59%

1-Tages-Spanne:

$2.12

$2.3299

1-Wochen-Bereich:

$1.79

$2.3299

52-Wochen-Spanne:

$1.085

$3.65

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Firmenname

C 4 Therapeutics Inc

Sektor

Healthcare (1110)

Branche

Biotechnology (622)

Telefon

(617) 231-0700

Adresse

490 ARSENAL WAY, WATERTOWN

Mitarbeiter

110

Twitter

Nächster Verdiensttermin

2025-02-24

Neueste SEC-Einreichungen

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CCCC C 4 Therapeutics Inc	2.30	209.34M	20.76M	-132.49M	-108.55M	-2.67
VRTX Vertex Pharmaceuticals Inc	481.01	121.15B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.04	82.43B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	826.25	52.25B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	329.35	44.59B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	370.64	40.07B	4.98B	69.60M	525.67M	0.5198

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-02	Eingeleitet	TD Cowen	Buy
2025-09-17	Eingeleitet	Barclays	Overweight
2025-09-15	Hochstufung	Stephens	Equal-Weight → Overweight
2025-09-04	Eingeleitet	Guggenheim	Buy
2024-12-19	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-11-18	Eingeleitet	Stephens	Equal-Weight
2024-01-29	Hochstufung	JP Morgan	Underweight → Neutral
2023-12-13	Hochstufung	Stifel	Hold → Buy
2023-02-24	Hochstufung	Credit Suisse	Underperform → Neutral
2023-02-24	Herabstufung	JP Morgan	Neutral → Underweight
2022-11-04	Herabstufung	JP Morgan	Overweight → Neutral
2022-10-11	Eingeleitet	Morgan Stanley	Underweight
2022-04-28	Eingeleitet	Credit Suisse	Underperform
2022-04-11	Herabstufung	BofA Securities	Buy → Neutral
2022-03-10	Eingeleitet	JP Morgan	Overweight
2022-02-11	Fortgesetzt	BMO Capital Markets	Outperform
2022-02-10	Eingeleitet	Wells Fargo	Equal Weight
2021-11-23	Eingeleitet	BofA Securities	Buy
2021-10-14	Eingeleitet	SVB Leerink	Mkt Perform
2021-09-30	Eingeleitet	Stifel	Hold
2021-06-04	Eingeleitet	H.C. Wainwright	Buy
2021-03-31	Eingeleitet	BMO Capital Markets	Outperform
2020-10-28	Eingeleitet	UBS	Buy
2020-10-27	Eingeleitet	BMO Capital Markets	Outperform
2020-10-27	Eingeleitet	Jefferies	Buy

Alle ansehen

C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten

12:54 PM

Brookline Capital Raises Price Target for C4 Therapeutics (CCCC) to $30 | CCCC Stock News - GuruFocus

12:54 PM

12:12 PM

CCCC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

12:12 PM

09:28 AM

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - Investing News Network

09:28 AM

08:34 AM

C4 Therapeutics doses first patient in phase 2 myeloma trial - Investing.com

08:34 AM

07:44 AM

C4 Therapeutics Doses First Patient in Phase 2 Trial of Cemsidomide Combination Therapy in Multiple Myeloma - marketscreener.com

07:44 AM

07:10 AM

Investor watch: C4 Therapeutics fireside chats in Boston and Miami - Stock Titan

07:10 AM

07:00 AM

New oral myeloma drug from C4 Therapeutics enters Phase 2 test - Stock Titan

07:00 AM

Feb 20, 2026

What valuation multiples suggest for C4 Therapeutics Inc. stock2025 Price Action Summary & Short-Term High Return Strategies - mfd.ru

Feb 20, 2026

Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential - Yahoo Finance

Feb 20, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Bitget

Feb 20, 2026

Feb 19, 2026

C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Feb 19, 2026

Feb 18, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 18, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Feb 18, 2026

Feb 17, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 17, 2026

Feb 14, 2026

Will C4 Therapeutics Inc. stock outperform tech sector in 2025Weekly Trend Recap & High Accuracy Investment Entry Signals - mfd.ru

Feb 14, 2026

Retail Trends: Is C4 Therapeutics Inc. stock a buy for dividend growth2025 Biggest Moves & Verified Technical Trade Signals - mfd.ru

Feb 14, 2026

Is C4 Therapeutics Inc. stock dividend yield sustainable2025 Retail Activity & Smart Allocation Stock Tips - mfd.ru

Feb 14, 2026

What is C4 Therapeutics Inc.’s valuation compared to sectorEarnings Risk Summary & Accurate Entry/Exit Alerts - mfd.ru

Feb 14, 2026

Can C4 Therapeutics Inc. reach all time highs this yearWeekly Gains Summary & Weekly Top Performers Watchlists - mfd.ru

Feb 14, 2026

Feb 13, 2026

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 13, 2026

Feb 11, 2026

C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference - MarketBeat

Feb 11, 2026

Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan

Feb 11, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 11, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 11, 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Globe and Mail

Feb 11, 2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 11, 2026

Feb 10, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Feb 10, 2026

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 10, 2026

Institutional investors may adopt severe steps after C4 Therapeutics, Inc.'s (NASDAQ:CCCC) latest 11% drop adds to a year losses - simplywall.st

Feb 10, 2026

Feb 09, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 09, 2026

New C4 Therapeutics hire receives options on 162,880 shares - Stock Titan

Feb 09, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 09, 2026

Feb 06, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com

Feb 06, 2026

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 06, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 06, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics

Feb 06, 2026

Feb 05, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 05, 2026

Feb 04, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Feb 04, 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Investing News Network

Feb 04, 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewswire Inc.

Feb 04, 2026

Feb 03, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Feb 03, 2026

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 03, 2026

Feb 02, 2026